The transfer of genomic information into the primary RNA sequence can be altered by RNA editing. We have previously shown that genomic variants can be RNA-edited to wild-type. The presence of distinct "edited" iduronate 2-sulfatase (IDS) mRNA transcripts ex vivo evidenced the correction of a nonsense and frameshift variant, respectively, in three unrelated Hunter syndrome patients. This phenomenon was confirmed in various patient samples by a variety of techniques, and was quantified by single-nucleotide primer extension. Western blotting also confirmed the presence of IDS protein similar in size to the wild-type. Since preliminary experimental evidence suggested that the "corrected" IDS proteins produced by the patients were similar in molecular weight and net charge to their wild-type counterparts, an in vitro system employing different cell types was established to recapitulate the site-specific editing of IDS RNA (uridine to cytidine conversion and uridine deletion), and to confirm the findings previously observed ex vivo in the three patients. In addition, confocal microscopy and flow cytometry analyses demonstrated the expression and lysosomal localization in HEK293 cells of GFP-labeled proteins translated from edited IDS mRNAs. Confocal high-content analysis of the two patients' cells expressing wild-type or mutated IDS confirmed lysosomal localization and showed no accumulation in the Golgi or early endosomes.
INTRODUCTION
The transfer of genomic information into the primary RNA sequence can be altered by RNA editing at either the transcriptional or posttranscriptional level. Initially, this mechanism was thought to be quite rare in human cells (Bass, 2002) . However, over the last few years, multiple studies, both computational and experimental, have shown that RNA editing contributes extensively to the complexity evident at both the transcriptome and proteome levels (Bazak et al., 2014; Chen, 2013;  Chen & Bundschuh, 2012; Daniel, Silberberg, Behm, & Ohman, 2014; Kleinman, Adoue, & Majewsk, 2012; Li & Maso, 2014; Li et al., 2011; Peng et al., 2012; Rieder, Staber, Hoopengardner, & Reenan, 2013; Savva & Reenan, 2014; Xu & Zhang 2014; Zhu et al., 2012) . In facilitating the genome-wide comparison of DNA and RNA sequences, the development of next-generation sequencing technology has served to greatly speed up studies of RNA editing (Chen et al., 2014; Piskol, Ramaswami, & Li, 2013) . RNA editing is now recognized as a key level of regulation that is responsible for modulating a variety of cellular functions including protein activity, alternative mRNA splicing, and the alteration of miRNA target sites (Kim, Hur, & Kim, 2016) . It should however be appreciated that the amount of RNA editing observed actually represents a population average of cells exhibiting a broad spectrum of rates of editing leading to the emergence of subsets of cells with differing informational content at the RNA level (Harjanto et al., 2016) .
A number of different forms of mRNA editing have been reported in the human genome (dbRES) [http://bioinfo.au.tsinghua.edu.cn/dbRES] and several mechanisms have been described, ranging from co-, postor co-post-transcriptional nucleotide modification, to nucleotide insertion or deletion (Bazak et al., 2014) . In human, RNA editing was first described as a cytidine to uridine (C-to-U) conversion in apolipoprotein B (APOB) primary transcripts by hydrolytic deamination giving rise to major alternative isoforms in the intestine (APOB48) and liver (APOB100), respectively (Navaratnam & Sarwar, 2006; Wedekind, Dance, Sowden, & Smith, 2003) . RNA editing is also known to modify RNAs in such a way as to introduce amino acid substitutions causing human genetic disease (Slotkin & Nishikura, 2013) .
Cytidine (C) to uridine (U) and adenosine (A) to inosine (I) transitions are the best characterized mammalian mRNA editing mechanisms reported to date. Generally, in mammalian cells, C to U and A to I changes have been observed in both coding and noncoding sequences, including microRNAs; dysregulation can lead to pathogenesis (Gott, 2011; Grohmann et al., 2010; Maas, Kawahara, Tamburro, & Nishikura, 2006; Ramaswami & Li, 2016) .
Far less common is the U-to-C editing of mRNA (and tRNA) that has been observed in both the nucleus and mitochondria of mammals (Niavarani et al., 2015; Villegas, Müller, Arredondo, Pinto, & Burzio, 2002) ; at present, the underlying enzymatic processes have not been elucidated. In human, the transcript of the Wilms' tumorsusceptibility gene, WT1, undergoes RNA editing by U-to-C conversion, thereby affecting the transcriptional repression function of the WTl protein (Mrowka & Schedl, 2000; Sharma, Bowman, Madden, Rauscher, & Sukumar, 1994) . U-to-C RNA editing has also been identified in long primary mi-RNAs (pri-miRNAs) (Blow et al., 2006; GriffithsJones, Saini, van Dongen, & Enright, 2008 ).
An additional mechanism, U deletion mRNA editing, was first reported as a posttranscriptional modification of the RNA sequence in kinetoplastids, a group of flagellate protozoa (Estévez & Simpson, 1999; Osato et al., 2009 ). However, evidence has emerged for the fairly frequent occurrence of U insertion editing in the human genome, where it represents a mechanism capable of creating different protein isoforms (Zougman, Ziółkowski, Mann, & Wiśniewski, 2008) . Although the site specificity and basic mechanism of U insertion editing have not been experimentally demonstrated in all cases (Chen & Bundschuh, 2012) , it has been shown in the trypanosomatids that specificity is determined by complementary guide RNAs that act in trans to guide the RNA editing core complex (RECC, the 20S editosome) to the site of U insertion or U deletion by base pairing (Aphasizhev & Aphasizheva, 2011; Cruz-Reyes, Zhelonkina, Rusche, & Sollner-Webb, 2001 ). It was recently reported in trypanosomatids that this type of editing serves to correct frameshifts, introduce translation punctuation (start and stop) signals, and can even add hundreds of uridines to create novel protein coding sequences (Aphasizheva & Aphasizhev, 2016) .
More recently, a strategy based upon artificial RNA-guided editing machinery has been developed to reprogram genetic information at the RNA level, and it has been shown that such a strategy is capable of repairing disease-relevant genes, such as CFTR, not only in mammalian cell culture but also in simple organisms (Reautschnig, Vogel, & Stafforst, 2016) . Previously, we reported that human iduronate 2-sulfatase (IDS) gene variants affecting function were RNA-edited ex vivo by an as-yet unidentified mechanism, which led to the expression of variable amounts of nonmutated (i.e., wild-type) IDS transcripts in a tissue-dependent fashion (Lualdi et al., 2010 et al., 2017) are sequence variants with the potential to impact RNA processing in some way. This is how, during the course of IDS RNA analysis, we observed, in three unrelated male (hemizygous) Hunter syndrome patients, evidence of ex vivo correction (at the RNA level) of their gene lesions characterized at the DNA level (Lualdi et al., 2010) .
The presence of two distinct "edited" IDS mRNA transcripts (U-to-C and delU, correcting a nonsense variant and a frameshift variant, respectively) in different patients, was confirmed in various tissues and cell lines from the patients by several different techniques and quantified by single-nucleotide primer extension (SNuPE). Western blotting analysis confirmed the presence of IDS precursor protein similar in size to the wild-type. We were left with the intriguing possibility that an mRNA correction mechanism akin to RNA editing had been activated in our patients. Here, we have confirmed by SDS-PAGE Western blot that the "corrected" IDS proteins, synthesized from edited IDS mRNAs produced by the patients, are similar in terms of molecular weight and net charge to their wild-type counterparts. Prompted by this experimental evidence, an in vitro system, employing different cell types, was used to recapitulate the site-specific editing of RNA (both U-to-C conversion and U deletion), and to confirm the findings previously observed ex vivo in the three patients. In addition, confocal microscopy, flow cytometry, and imaging flow cytometry (IFC) analyses provided evidence for both the expression and lysosomal localization in HEK293 cells of GFP-labeled proteins translated from edited IDS mRNAs. Confocal high-content analysis of the two patients' cells expressing wildtype or mutated IDS confirmed lysosomal localization and showed no accumulation in the Golgi or early endosomes.
MATERIALS AND METHODS

Patient and control samples
Fibroblast and lymphoblast cell lines were grown from the two unrelated Italian MPS II patients (pts), hemizygous for the IDS genomic variants, c.22C>T and c.9_10insT (by contrast, at the RNA level, the presence of edited IDS mRNA transcripts c.22U>C and c.10delU, respectively, was evident). The c.22C>T and c.9_10insT variants, both of which are located in exon 1, predicted the truncating variants p.R8X and p.P4SfsX43. Fibroblast and lymphoblast cell line samples from a wild-type male individual were used as negative controls. Fibroblasts harboring the IDS mutant p.W12X (c.35G>A), which proved not to be prone to RNA editing, were also included in the experiments.
The patient's samples were obtained from the "Cell Line and DNA Biobank from patients affected by Genetic Diseases" (Filocamo et al., 2014) . Owing to the paucity of Biobank samples, only one of the two patients known to harbor the c.22C>T (R8X) was studied in the present work.
Ethical aspects
Following ethical guidelines, all samples for analysis and storage were obtained with the patients' (and/or the legal guardian's) written informed consent. Consent was sought using a form approved by the local Ethics Committee.
Variant nomenclature
According to current variant nomenclature recommendations (Human (Lualdi et al., 2010) , the former variant designation is used throughout the text in order to maintain continuity.
Cell culture
In-house established human fibroblasts and the commercially available human cell lines, HeLa and HEK293, were cultured according to standard procedures and maintained in RPMI medium (EuroClone, Gibco, Paisley, UK) containing 15% FCS and penicillin/streptomycin, in a humidified atmosphere containing 5% CO 2 at 37°C. The human fibroblasts were tested for mycoplasma contamination before use.
Biochemical studies on IDS protein from patient cell lines
Cells collected for all electrophoresis experiments were counted, washed in TBS, and solubilized in Laemmli sample buffer for SDSreduced-PAGE and 2D-PAGE, or in Tris/Boric acid/ EDTA buffer for Native-PAGE. Sample concentrations were determined by means of a bicinchoninic acid protein assay.
Native-PAGE
Samples (50 g) were solubilized in 90 mM Tris, 80 mM boric acid and EDTA buffer at pH 8.6 containing phosphatase and protease inhibitor cocktail and loaded onto a gel (T% 8-16) with the same buffer in a Protean II XI system (Bio-Rad, Hercules, CA).
SDS-reduced-PAGE
Samples (50 g) were solubilized in Laemmli sample buffer containing 50 mM DTE (1,4-Dithioerythritol) and phosphatase and protease inhibitor cocktail. Samples were then boiled for 10 min and separated in a SDS-PAGE (T% 8-16) with a Protean II XI system (Bio-Rad).
2D-PAGE
The solubilized samples (200 g) were cleaned and precipitated using an ice-cool mixture of tri-n-butyl-phosphate-acetone-methanol with a ratio of 1:12:1 as previously reported (Bruschi et al., 2005) with some modifications. Briefly, this mixture was added to each sample to reach a final acetone concentration of 80% (v/v) and incubated for 90 min at 4°C. The precipitate was pelleted by centrifugation at 2,800g for 20 min at 4°C. Supernatant was discarded, and the pellet was washed with 1 ml tetrahydrofuran precooled on ice. After centrifugation at 10,000g for 10 min at 4°C, the pellet was air-dried, dissolved in the sample focusing solution (7M urea, 2M thiourea, 4% [w/v] CHAPS, and 50 mM DTE), and loaded onto home-made nonlinear pH 3-10 soft-IPG strips (18 cm long, 3 mm wide, 0.5 mm thick) (Bruschi et al., 2003) . Strip reswelling was carried out overnight at room temperature in the focusing solution, 7M urea, 2M thiourea, 2% (w/v) CHAPS, 15 mM DTE, and 0.6% (v/v) carrier ampholyte cocktail, containing 40% of the pH 3.5-10 and 60% of the pH 4-8 intervals.
Proteins were focused at ≤50 mA per strip at 20°C, using a progressively increasing voltage for a total of 90,000 Vh. An equilibration step was performed for 30 min in the equilibration buffer containing 6 M urea, 50 mM Tris-HCl pH 8.8, 2% (w/v) SDS, 30% (v/v) glycerol, and a trace of bromophenol blue. In the second dimension, proteins were separated on an SDS-PAGE gel (T% 8-16) with a Protean II XI system (Bio-Rad).
Western blotting
After the electrophoretic separation, the samples were transferred 
Immunoprecipitation
Immunoprecipitation by anti-IDS antibody (Abnova) was performed with 1 mg protein from whole-cell lysates. After precleaning by protein A Sepharose, samples were incubated with anti-IDS antibody overnight at 4°C with gentle rotation. The protein A-Sepharose beads were then washed extensively with washing buffer and eluted with 2D-PAGE focusing solution. The bound proteins eluted from the beads were separated on 2D-PAGE, and the gels were subjected to silver staining.
Construction of full-length IDS cDNA vector for in vitro expression
RT-PCR products of full-length IDS cDNAs, obtained using primers located in the 5 ′ UTR and 3 ′ UTR, respectively (Lualdi et al., 2010) , were cloned into the plasmid vector pcDNA3.1/V5-His-TOPO, containing the CMV promoter and T7 promoter (see map) [http://tools.
invitrogen.com/content/sfs/manuals/pcdna3.1topota_man.pdf], to generate IDS cDNA constructs as follows: (1) 
Transfection of the full-length IDS cDNA constructs and characterization of transcripts by SNuPE analysis
Eight micrograms of each vector were transfected by Lipofectamine 
Confocal microscopy
Transfection with vector p-IDS-
Flow cytometric analysis
All flow cytometric samples were acquired on a four laser Gallios (Beckman Coulter, Brea, CA), whereas, after acquisition, compensation and data analysis were performed with Kaluza software (Beckman Coulter). HEK293 cells were evaluated on the basis of their level of GFP protein expression.
IFC analysis
Cells were analyzed in the ImageStreamX Mark II imaging flow cytometer (Amnis Corporation, Seattle, WA) equipped with a MultiMag system. Data were acquired using INSPIRE acquisition software (Amnis Corporation). Five thousand events were recorded using a 20x objective in order to perform quantitative analyses of samples, whilst 1,000 events were collected with both 40x and 60x objective lenses to obtain an improved view of the analyzed colocalization of GFP and LysoTracker.
Upon focus, cells were initially identified from the bright-field images by using an algorithm recommended by the manufacturer, the Gradient RMS (root mean square) feature. Since HEK293 is an adherent cell line that tends to form aggregates even when resuspended strongly, we took advantage of two other features of INSPIRE software, Area and Aspect Ratio (the smallest width divided by the longest;
for single cells, this ratio should usually be 0.8-1), which allowed us to specifically focus our attention on single cell events. Thanks to these features, we were able to optimize sample collection by recording only those events corresponding to perfectly in-focus single cells. To perform this analysis, four ImageStream channels were used: channel 1 for the bright-field, channel 2 for GFP (excited by a 488-nm laser), channel 5 for LysoTracker (excited by a 642-nm laser).
Data were then analyzed using IDEAS 6.0.3 software (Amnis Corporation). Compensation was set on the basis of a matrix calculated by IDEAS software using single-stained samples (GFP and LysoTracker) obtained with the same laser setting used for acquisition but with the bright-field light switched off, as suggested by the manufacturer. 
Confocal high-content imaging and analysis of IDS protein expression and subcellular localization
RESULTS
Biochemical studies on IDS protein from patient cell lines
Western blots of SDS-reduced-PAGE and native-PAGE gels revealed a unique protein product, with a molecular weight comparable to that of IDS (MW = 61.9 kDa) in both patient samples (p.R8X and p.P4SfsX43); a reduced protein concentration was noted exclusively in the patient harboring p.P4Sfs, as compared with the control (Fig. 1) .
To verify the absence of any difference in molecular weight and/or net charge modification of IDS protein from the patients as compared with the control, a western blot of two-dimensional gel electrophoresis was performed. Unfortunately, the IDS antibodies employed did not detect any protein spots (data not shown). To resolve this prob- (p.P4SfsX43), and c.35G>A (p.W12X)] were inserted into the F I G U R E 1 Representative western blots on lymphoblasts from Hunter syndrome patients (p.P4Sfs and p.R8X) and controls (WT). IDS protein detection under SDS-reducing (A) and native (B) conditions. The western blots, obtained using an anti-IDS antibody, exhibited a major band in samples from both controls and patients, which exhibited identical electrophoretic migration properties to that of the IDS protein reference noted in SDS-PAGE. C: Bar plot of IDS protein expression levels. The values from the densitometric analysis are expressed as optical density (OD) and revealed a decrease in IDS protein expression between the control and the patient harboring p.P4Sfs. The values quoted represent the means of triplicate measurements. Error bars represent standard deviations. Antitubulin was used as a housekeeping control. GenBank NP_000193.1 F I G U R E 2 Representative two-dimensional gel electrophoresis of immunoprecipitation from Hunter syndrome patients (p.P4Sfs and p.R8X) and controls (WT). Representative silver staining of the anti-IDS immunoprecipitation revealing three spots (circled) corresponding to the molecular weight of IDS protein. These three spots exhibited optical density changes comparable to those noted in the western blot experiments; however, no difference in either molecular weight or isoelectric point was evident between the control and the patient harboring p.R8X. It should be noted that the p.P4Sfs sample is not visible, probably due to its low expression (also observed by western blotting). GenBank NP_000193.1 plasmid vector pcDNA3.1/V5-His-TOPO, containing the CMV promoter and T7 promoter, and then introduced by lipid-mediated transfection into: (1) fibroblasts from the two patients exhibiting the RNA editing-like mechanism(s), conversion, and deletion, respectively; (2) normal fibroblasts; and (3) commercially available human cell lines, namely, HeLa and HEK293. To quantify the amount of nucleotide correction (U>C and delU), SNuPE of RT-PCR products was performed with specific primers as previously described (Lualdi et al., 2010) .
The SNuPE results showed that the plasmid constructs harboring p.R8X and p.P4SfsX43 yielded the expected transcripts (i.e., both mutated and corrected to wild-type) in cellula, not only when they were transfected into Hunter syndrome patient fibroblasts (which of course display the RNA editing-like phenomenon), but also when they were transfected into healthy donor fibroblasts and commercially available cell lines, namely, HeLa and HEK293. As indicated in Table 1 , the extent of nucleotide correction ranged from 17% to 53% for the U deletion [c.9_10insT (p.P4SfsX43)], and from 0% to 63% for the conversion of U to C [c.22C>T (p.R8X)], depending upon the type of transfected cell. In agreement with the ex vivo results observed in the patients in the previous study (Lualdi et al., 2010) (Fig. 4A and B) . By contrast, expression levels of the IDS(W12X)-GFP fusion protein, bearing a stop codon that is predicted to lead to premature termination of translation (but empirically shown not to be prone to mRNA correction) were, as expected, scarcely visible (Fig. 4C ).
Confocal microscopy analysis: Evidence of IDS-GFP expression and IDS-GFP lysosomal localization in HEK293 cells transfected with the pAcGFP1-N vector harboring IDS(WT), IDS(R8X), and IDS(W12X)
3
Evidence of lysosomal localization
LysoTracker stained acidic cellular compartments in all cells. Overlaying red and green fluorescence into a merged image revealed those
regions where both IDS(WT)-GFP and IDS(R8X)-GFP colocalized with
LysoTracker (yellow staining indicated by arrows), suggesting IDS-GFP lysosomal localization, albeit only partial (Fig. 4, fourth column, A and   B ).
Flow cytometry analysis: Quantification of IDS-GFP expression in HEK293 cells transfected with the pAcGFP1-N vector carrying IDS(WT), IDS(R8X), and IDS(W12X)
As an adherent cell line, HEK293 cells tend to stick together. For this reason, and in order to avoid doublets or triplets that could alter the proportions of positive GFP events, Side SCatter (SSC) peak width was plotted against SSC peak height, allowing clear discrimination between single cells and doublets (Fig. 5A) . These doublets were then gated out and single cells were analyzed for their GFP expression. As shown in Figure Flow cytometry quantification analysis therefore confirmed that the amount of corrected-fusion-IDS protein was comparable to that of the wild-type IDS protein.
IFC analysis: Evidence of lysosomal localization and quantification of IDS-GFP expression in HEK293 transfected cells with pAcGFP1-N vector harboring IDS(WT) and IDS(R8X)
In order to perform a semiquantitative analysis of the samples from transfected cells, we acquired 5,000 cellular events using a 20x objective. We further optimized the analysis by focusing exclusively on events that corresponded to perfectly in-focus single cells (Fig. 6A and
B). Data obtained for both IDS(WT)-GFP and IDS(R8X)-GFP
F I G U R E 3 Capillary electrophoretic patterns obtained from transfection of expression vectors. The expression vectors contained (P4Sfs)-, (R8X)-, and (W12X)-IDS cDNA (A, B, and C, respectively) into patient fibroblasts (a, b), normal control fibroblasts (c), and the HEK293 (d) and
HeLa (e) cell lines. Detection primers were designed so that their 3 ′ ends corresponded to the nucleotides (nt) closest to the uracils (thymines) to be corrected; that is at the -1 position (forward primer) for the single base deletion, and at the +2 position (reverse primer) for the base conversion (Lualdi et al., 2010) . Either ddCTP (base deletion, black peak) or ddGTP (base conversion, blue peak) would be incorporated when the mutant IDS mRNAs were corrected, whereas ddTTP and ddATP would be added if the mutant IDS mRNAs remained uncorrected. In the case of base deletion, the black peak would denote the normal nt C, whereas the red peak would denote the inserted (unedited) nt T (A). In the case of base conversion (detection primer being the reverse), the blue peak would denote the normal (edited) nt G (C), whereas the green peak would denote the mutated (unedited) nt A (T) (B). In addition, in the case of G>A conversion (W12X), using a reverse primer, only ddATP (red peak) was added as the mutant IDS mRNA remained uncorrected (C). GenBank NP_000193.1 fusion protein expression in HEK293 showed comparable percentages (Fig. 6C) , thereby confirming what had already been observed by flow cytometry. In contrast to classical cytometry, through which we could only establish whether two markers of interest (LysoTracker and GFP)
were coexpressed in the same cell, IFC also allowed us to determine whether or not LysoTracker and GFP colocalized. To identify the cell subpopulation bearing the colocalization of interest, we applied a feature called "bright detail similarity" to a custom mask (Fig. 6D) . Through the algorithm obtained, we were able to define a cluster of the best images of those events exhibiting high expression of both markers in the same position of the cell surface at the same time. This analytical strategy was also applied to cellular events acquired with both 40x and 60x objectives, in order to perform a qualitative analysis leading to good lysosomal localization pictures of both IDS(WT)-GFP and IDS(R8X)-GFP fusion proteins expressed in vitro ( Fig. 6E and F) . Overall, analysis of the data allowed us to confirm that the IDS protein produced using the edited mRNA as template was comparable to the wild-type IDS protein both in terms of its amount and its lysosomal localization.
Confocal high-content screening system: Imaging and analysis of IDS protein expression and subcellular localization in patient cell lines
High-content imaging analysis was performed on fibroblasts from control and Hunter syndrome individuals using the Opera Phenix system (PerkinElmer). This analysis revealed that in control fibroblasts wildtype IDS protein is expressed and colocalizes with LAMP-1, a lysosomal marker. Colocalization of the two signals was higher than 90% (Fig. 7A) . By contrast, the expression of W12X-IDS in fibroblasts from a Hunter syndrome patient was extremely low (an ∼100-fold decrease as compared with the expression of wild-type IDS) with no colocalization with the lysosome marker LAMP-1 (Fig. 7B) . However, fibroblasts from Hunter syndrome patients bearing either the p.R8X (Fig. 7C ) or p.P4Sfs (Fig. 7D ) variant display very high levels of expression of the edited-to-wild-type mutant protein (a ∼50-fold increase as compared with expression of wild-type IDS) that accumulates inside the cells.
Colocalization of edited-to-wild-type R8X-or P4Sfs-IDS with LAMP-1 was low (approximately 10%). We also analyzed the colocalization Fig. 7C and D) .
Review of available literature and bioinformatics analysis
To ascertain whether there might be other human IDS target sites for RNA editing in addition to those investigated here, we comprehensively screened the relevant literature: a computational study that aimed to determine the extent of RNA editing in the human transcriptome identified a single U-to-A editing site in an intronic position of the unspliced IDS mRNA (chrX 1,48E+08) (Kleinman et al., 2012) . We also surveyed bioinformatics software resources available online. The RADAR database [http://rnaedit.com/] lists three RNA A-to-I editing events affecting three distinct sites in the IDS gene, two intronic (chrX 1,48567508E+08 and 1,48567509E+08) and one exonic (chrX 1,48577934E+08). We also queried the DARNED database [http://darned.ucc.ie/], but no IDS editing sites were found.
DISCUSSION
The twin aims of this work were (1) to elucidate further the biochemical features of the IDS proteins encoded by the mutant mRNAs (p.P4SfsX43 and p.R8X) edited-to-wild-type, which we previously observed in three patients affected by Hunter syndrome and (2) to recapitulate in vitro the site-specific editing of RNA, namely, the U-to-C conversion and U deletion (Lualdi et al., 2010) .
The biochemical analysis panel, including the western blotting of proteins in native-PAGE, reducing SDS-PAGE, and two-dimensional gel electrophoresis of immunoprecipitated proteins, confirmed the presence, in the patient's cell line harboring p.R8X, of wild-type IDS protein with similar amount, molecular weight, and charge properties to those noted in the control. In the patient's cell line harboring p.P4Sfs, the wild-type IDS protein exhibited similar molecular weight and charge properties to that of the control, but a comparatively low amount of protein compared with the control. Therefore, the wild-type protein detected could only have been translated from the edited IDS transcripts identified ex vivo in the two Hunter syndrome patients. The in vitro expression system, developed to investigate these observations further, employed different human cell lines and successfully recapitulated the site-specific editing of mutated RNA.
Intriguingly, in cellula, plasmid constructs harboring both p.R8X and p.P4SfsX43 yielded both mutated and edited transcripts, not only when they were transfected into fibroblasts cultured from the same Hunter syndrome patients (which were known to be positive for the RNA editing phenomenon), but also when they were transfected into healthy donors' fibroblasts and commercially available HeLa and HEK293 cell lines (Table 1) . Whether editing occurs or not therefore appears to be an inherent property of the target sequence. However, the observed extent of the nucleotide correction may depend upon the F I G U R E 5 Flow cytometric analysis of GFP expression. A: Dot plot of HEK293 side scatter (SSC) peak width against SSC peak height set to gate on single cells and to exclude aggregates. B: Single cell population analyzed for GFP level of expression. Considered a slight autofluorescence of cultured cells in the first emission channel (FL1), the negative is set on CTRL (not expressing GFP) autofluorescence. HEK 293 cells harboring IDS(R8X) display a level of GFP expression (light gray striped histograms in left side graphics and black dots in right side dotplots) that almost overlaps with the IDS(WT) sample (57% and 54%, respectively). In HEK293 cells harboring IDS(W12X), the GFP expression is strongly reduced (16%), whereas the mean fluorescence intensity (MFI) is distinctly lower. GenBank NP_000193.1 type of transfected cells but may also be regulated by RNA secondary structure and the temporal expression of RNA editing enzymes in the same cell population, as described for known editing mechanisms, such as that occurring in APOB (Hwang et al., 2016) . Taken together, these results demonstrated that our in vitro system was able to recapitulate the putative correction mechanism and that this mechanism, acting independently of cell type, was likely to be dependent upon intrinsic characteristics of the editing sites.
In addition, at the protein level, confocal microscopy yielded evidence both for IDS-GFP expression and IDS-GFP lysosomal localization, albeit only partial, in HEK293 cells transfected with the pAcGFP1-N vector carrying IDS(p.R8X) (Fig. 4B) . Similar findings were obtained by flow cytometry and IFC analyses (Figs. 5 and 6 ). Based on these results, it is clear that our in vitro system was able to recapitulate the observed mechanism ex vivo, leading to partial restoration of a certain amount of wild-type IDS RNA and protein that appeared to have, at least to some extent, an appropriate lysosomal localization; somewhat unexpectedly, this occurred irrespective of the cell type employed.
To further investigate the finding of a partial lysosomal localization, we extended the analysis to other prominent cellular bodies in the patients' fibroblasts using the confocal high-content screening system, which enables automatic high-content imaging and analysis of thousands of individual cells visualized by high-resolution microscopy.
The screening performed on lysosomes, the Golgi apparatus, and early endosomes confirmed adequate, although somewhat low, lysosomal localization (approximately 10%) of the proteins encoded by F I G U R E 6 Image flow cytometric colocalization analysis. A: The histogram values derive from a feature (gradient RMS) that measures and plots the sharpness of an image, thereby determining its overall focus quality. In-focus cells are gated and then (B) analyzed on the basis of two physical qualities: aspect ratio and area of the brightfield. Aspect ratio was calculated based on brightfield as the ratio of cellular minor axis (width) to major axis (height). Round cells have an aspect ratio close to 0.8-1, whereas the elongated cells or clumps have a lower aspect ratio. We gated on round single cells of the correct dimension (area) for further analysis (gate "HEK293"). C: HEK293 cells were visualized on a dot plot based on their expression of GFP and LysoTracker. D: To improve the visual observations and identify the best images, a statistical analysis of double positive events similarity in the staining patterns was performed. The bright detail similarity values were calculated using an algorithm for colocalization based upon the relative intensities in individual pixels of a cell. Since each pixel has a spatial registry, pixel intensity values in different channels can be compared. IDS(WT) (E) and IDS(R8X) (F) colocalization are shown (yellow-orange in Ch02/Ch05). GenBank NP_000193.1 the mutant mRNAs (p.P4SfsX43 and p.R8X) edited-to-wild-type and clearly demonstrated that they did not accumulate in the Golgi nor in the early endosomes of the two patients' cell lines (Fig. 7C and D) .
Overall, these results concurred with those we previously reported in the Hunter syndrome patient samples (Lualdi et al., 2010) , but they still did not provide any obvious explanation for the deficiency of IDS enzymatic activity in our patient samples. The observed low residual enzymatic activity could in principle be explicable in terms of the preferential lysosomal degradation of the "corrected" proteins as demonstrated in a recent study of RNA editing in mammalian brain cells (Behm & Öhman, 2016) .
The only other report of an editing-like variant correction mechanism occurring in the context of a human disease gene has been that tentatively noted in the context of GNPTG (Velho et al., 2016) .
A homozygous c.[328G>T] transversion predicting a p. [Glu110Term] substitution was detected in siblings affected by another lysosomal disorder, mucolipidosis III gamma, but this variant was undetectable at the cDNA level (only the wild-type GNPTG sequence was evident).
Although this additional example of "enigmatic transcript correction" remains to be confirmed by in-depth analysis, we find it intriguing that it is also associated with a lysosomal disorder, particularly in the light of our above suggestion of the preferential lysosomal degradation of the "corrected" proteins.
The possible instructive role of the nucleotide sequence environment around the mRNA editing sites remains to be clarified. Our findings demonstrate that the ex vivo repair mechanism occurring in all cell types tested is likely to be critically dependent upon the intrinsic characteristics of the primary sequence/secondary structure of the mRNA editing sites themselves. Some proteins involved in the response to DNA damage may function in RNA metabolism (Kai, 2016) ; conversely, RNA processing proteins or protein complexes may be involved in the DNA damage response or may even exhibit DNA repair activity themselves (Jobert & Nilsen, 2014) . RNA processing enzymes are known to play a role in the maintenance of genomic integrity and in the integration and interconnection of DNA and RNA processing pathways in the eukaryotic nucleus. Currently available data point to an emerging role for specific base excision repair (BER) proteins in RNA metabolism and RNA surveillance pathways (Jobert & Nilsen, 2014) . The unique ability of BER DNA glycosylases to recognize even subtle chemical modifications of nucleic acid bases may serve to distinguish normal and F I G U R E 7 Representative images obtained from confocal high-content analysis of cells expressing wild-type or mutated IDS. IDS protein (red) immunolocalization in fibroblasts from control individuals (wt-IDS) and from Hunter syndrome patients (P4Sfs-, R8X-, and W12X-IDS). A: Wildtype IDS protein is expressed in fibroblasts from a healthy individual and colocalizes with LAMP-1, a lysosome marker (green). B: In fibroblasts from Hunter syndrome patients bearing the p.W12X variant, mutant IDS is expressed at a very low level, and does not colocalize with LAMP-1. Fibroblasts from Hunter syndrome patients bearing either the p.R8X (C) or the p.P4Sfs (D) variants exhibit very high levels of expression of the edited mutant protein, which partially colocalizes with LAMP-1 (lysosome). However, no colocalization is evident with the Golgi marker, giantin (yellow), or the early endosome marker, EEA1 (yellow). Bar = 10 m. GenBank NP_000193.1 aberrant RNA molecules (Jobert & Nilsen, 2014) . We may therefore speculate that proteins involved in the signaling and repair of DNA damage might also function as part of a novel mRNA correction system. Such a system could in principle be recruited to the task of experimentally correcting inherited gene lesions at the RNA level, thereby opening up new therapeutic avenues for the future.
We conclude that despite the editing of the mutant IDS mRNA molecules to wild-type, and despite these mRNAs being translated, the fate of the protein products of translation of these mRNAs is qualitatively and quantitatively different from that expected of normal wildtype IDS. We rationalize the situation as follows: first, the IDS mRNA transcripts harboring the nonsense/frameshift variants have managed to elude nonsense-mediated mRNA decay. Second, a sizeable proportion of the mutant IDS mRNA transcripts have been edited to wildtype. Third, despite the correction of the IDS mRNA sequence by editing so that they can be properly translated, the cell still appears to treat "corrected" IDS protein translated from these mRNAs differently from IDS protein translated from wild-type IDS mRNAs in normal individuals. Thus, notwithstanding the success of the mRNA editing correction process, it may well be that these essentially wild-type IDS mRNAs have already been tagged by the cell as "abnormal" and hence all subsequent translation products have, at an early stage, been earmarked for destruction despite the evident translatability of the edited IDS mRNAs (Inada, 2017; Simms, Thomas, & Zaher, 2017) .
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